Rosa Tejedor1, Albert Feliu-Soler2, Juan C Pascual3, Ausiàs Cebolla4, Maria J Portella3, Joan Trujols3, José Soriano2, Víctor Pérez3, Joaquim Soler5. 1. Divisió Salut Mental, Althaia, Xarxa Assistencial Universitaria de Manresa. FP, Manresa, España. 2. Servei de Psiquiatria, Hospital de la Santa Creu i Sant Pau, Barcelona, Universitat Autònoma de Barcelona (UAB), Barcelona, España. 3. Servei de Psiquiatria, Hospital de la Santa Creu i Sant Pau, Barcelona, Universitat Autònoma de Barcelona (UAB), Barcelona, España; Institut d'Investigació Biomèdica Sant Pau (IIB Sant Pau), Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, España. 4. Departament de psicologia bàsica, clínica i psicobiologia, Universitat Jaume I, Castelló, España; Centro de Investigación Biomédica en Red-Fisiopatología de la Obesidad y la Nutrición, CIBERobn, Santiago de Compostela, España. 5. Servei de Psiquiatria, Hospital de la Santa Creu i Sant Pau, Barcelona, Universitat Autònoma de Barcelona (UAB), Barcelona, España; Institut d'Investigació Biomèdica Sant Pau (IIB Sant Pau), Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, España. Electronic address: jsolerri@santpau.cat.
Abstract
INTRODUCTION: The Philadelphia Mindfulness Scale (PHLMS) is a brief questionnaire for assessing 2 key components of mindfulness: present moment awareness, and acceptance. This study was aimed at evaluating the psychometric properties of the Spanish version of PHLMS in a sample of participants with and without psychiatric conditions. MATERIAL AND METHODS: The Spanish version of the PHLMS was administered to a sample of 395 volunteers (256 of them with a psychiatric condition, and 130 from a student sample). RESULTS: Exploratory factor analysis found a two factor solution, which was also observed in the original version of the scale, with an explained variance of 44.02%. The scale showed good reliability (Cronbach α between 0.81 and 0.86), and an adequate convergent validity with other questionnaires of mindfulness and acceptance. The results also showed a similar discriminant validity to that in the original instrument validation between PHLMS and the clinical symptomatology reported. CONCLUSIONS: The Spanish version of the PHLMS is a psychometrically sound measure for assessing two core components of mindfulness (i.e. awareness and acceptance) in clinical and research settings.
INTRODUCTION: The Philadelphia Mindfulness Scale (PHLMS) is a brief questionnaire for assessing 2 key components of mindfulness: present moment awareness, and acceptance. This study was aimed at evaluating the psychometric properties of the Spanish version of PHLMS in a sample of participants with and without psychiatric conditions. MATERIAL AND METHODS: The Spanish version of the PHLMS was administered to a sample of 395 volunteers (256 of them with a psychiatric condition, and 130 from a student sample). RESULTS: Exploratory factor analysis found a two factor solution, which was also observed in the original version of the scale, with an explained variance of 44.02%. The scale showed good reliability (Cronbach α between 0.81 and 0.86), and an adequate convergent validity with other questionnaires of mindfulness and acceptance. The results also showed a similar discriminant validity to that in the original instrument validation between PHLMS and the clinical symptomatology reported. CONCLUSIONS: The Spanish version of the PHLMS is a psychometrically sound measure for assessing two core components of mindfulness (i.e. awareness and acceptance) in clinical and research settings.
Authors: Joaquim Soler; Matilde Elices; Alba Franquesa; Steven Barker; Pablo Friedlander; Amanda Feilding; Juan C Pascual; Jordi Riba Journal: Psychopharmacology (Berl) Date: 2015-11-27 Impact factor: 4.530
Authors: Andrea Salvador Zaragozá; Ana Soto-Rubio; Laura Lacomba-Trejo; Selene Valero-Moreno; Marian Pérez-Marín Journal: Curr Psychol Date: 2021-06-25
Authors: Joaquim Soler; Matilde Elices; Elisabeth Dominguez-Clavé; Juan C Pascual; Amanda Feilding; Mayte Navarro-Gil; Javier García-Campayo; Jordi Riba Journal: Front Pharmacol Date: 2018-03-20 Impact factor: 5.810